Abstract
Emerging diseases caused by coronaviruses of likely bat origin (e.g. SARS, MERS, SADS and COVID-19) have disrupted global health and economies for two decades.
Evidence suggests that some bat SARS-related coronaviruses (SARSr-CoVs) could infect people directly, and that their spillover is more frequent than previously recognized. Each zoonotic spillover of a novel virus represents an opportunity for evolutionary adaptation and further spread; therefore, quantifying the extent of this “hidden” spillover may help target prevention programs. We derive biologically realistic range distributions for known bat SARSr-CoV hosts and quantify their overlap with human populations. We then use probabilistic risk assessment and data on human-bat contact, human SARSr-CoV seroprevalence, and antibody duration to estimate that ∼400,000 people (median: ∼50,000) are infected with SARSr-CoVs annually in South and Southeast Asia. These data on the geography and scale of spillover can be used to target surveillance and prevention programs for potential future bat-CoV emergence.
Competing Interest Statement
P.D. served as a member of the WHO-China joint study on COVID-19 origins, is a current member of the Lancet COVID-19 Commission Taskforce on the Origins and Early Spread of COVID-19 and One Health Solutions to Future Pandemics, and was Chair of the IPBES Pandemics and Biodiversity Workshop. P.D. has made numerous public statements both independently, and as part of these groups, on the likely origins of COVID-19 and the need to assess risk and prioritize targeted surveillance for future disease emergence. L.F.W. serves on multiple committees for WHO, FAO and OIE on COVID-19 including assay and vaccine development and animal models; has ongoing research investigating the origin of COVID-19; and has made statements on this issue to the media.
Funding Statement
We acknowledge funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID-CREID U01AI151797 Titled EID-SEARCH), the Samuel Freeman Charitable Trust, Pamela Thye, The Wallace Fund, and an Anonymous Donor c/o Schwab Charitable. L.F.W. is supported by grants from NRF (NRF2012NRF-CRP001-056; NRF2016NRF-NSFC002-013), NMRC (MOH-OFIRG19MAY-0011; COVID19RF-003) and MOE (MOE2019-T2-2-130) of Singapore.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable - this paper does not contain human research data. It analyzes ecological data to infer risk patterns of spillover across a large geographical area.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability The datasets analyzed during the current study are available on Zenodo: https://zenodo.org/record/5251726#.YSWivEApAUE. Code Availability Code to replicate the analyses and figures is available on Zenodo: https://zenodo.org/record/5251726#.YSWivEApAUE.
